• Featured Product
  • KD/KO Validated

Alpha Galactosidase A Monoclonal antibody

Alpha Galactosidase A Monoclonal Antibody for IF, IHC, WB, ELISA

Host / Isotype

Mouse / IgG2a









Cat no : 66121-1-Ig


Alpha galactosidase A, galactosidase, alpha

Tested Applications

Positive WB detected inHeLa cells, HEK-293 cells, HepG2 cells, human kidney tissue, LNCaP cells, A431 cells
Positive IHC detected inhuman kidney tissue, human liver tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHepG2 cells

Recommended dilution

Western Blot (WB)WB : 1:3000-1:10000
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 1 publications below

Product Information

The immunogen of 66121-1-Ig is Alpha Galactosidase A Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Immunogen Alpha Galactosidase A fusion protein Ag7505
Full Name galactosidase, alpha
Calculated molecular weight 49 kDa
Observed molecular weight 49 kDa
GenBank accession numberBC002689
Gene symbol GLA
Gene ID (NCBI) 2717
Conjugate Unconjugated
Form Liquid
Purification Method Protein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

GLA, also named as Melibiase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.


Product Specific Protocols
WB protocol for Alpha Galactosidase A antibody 66121-1-IgDownload protocol
IHC protocol for Alpha Galactosidase A antibody 66121-1-IgDownload protocol
IF protocol for Alpha Galactosidase A antibody 66121-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Nat Commun

Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis

Authors - Sebastian Boland